Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 15/20 | 0.59 |
| ▸ | CHUK | O15111 | 13/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546118 | 0.90 | IKBKB (0.72) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3543166 | 0.87 | IKBKB (0.55) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3540510 | 0.87 | CYP1A2 (0.45) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3544075 | 0.86 | IKBKB (0.45) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3552707 | 0.85 | IKBKB (0.44) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3546968 | 0.85 | IKBKB (0.44) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3548558 | 0.85 | IKBKB (0.46) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3544016 | 0.85 | IKBKB (0.46) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3543608 | 0.84 | IKBKB (0.45) | IKBKBCHUKCDK2BTKITK | |
| SCHEMBL3548046 | 0.84 | IKBKB (0.50) | IKBKBCHUKCDK2BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | claimed |
| US-7683171-B2 | N,1-Dimethyl-7-phenyl-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-4-amine; treating inflammatory and immune diseases; cancer; I kappa B kinase (IKK) inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178393-A1 | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | IL4, IL5, IRAK4 | IKBKB 237/4885CHUK 828/4885CDK2 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.